## Summary
This paper tackles a clinically meaningful problem: moving beyond whole-image loose/control classification toward a structured pipeline for hip implant X-rays that first screens image fitness, then segments the standard 3 Charnley and 7 Gruen zones, and finally predicts zone-wise radiolucency/loosening. A concrete contribution is the extension of the Rahman et al. dataset with zone annotations and zone-level labels, and the paper reports strong internal performance plus a small blind external test.

## Strengths
- **The task formulation is more clinically actionable than prior whole-image classification setups.** Rather than only predicting loose vs. control, the method outputs standard **Charnley/Gruen zonal localization** and zone-level loosening labels, which is directly aligned with how clinicians assess prosthesis loosening (“dividing the femoral region into 7 Gruen zones, and the cup region into 3 Charnley zones”).
- **The paper appears to make a substantive annotation contribution on top of an existing dataset.** Section 3.1 describes new expert-created annotations including the 10 zones, landmarks, and an Excel sheet with fit/not-fit, zone-wise loosening, not-visible zones, and other implant findings. This is more specific than generic relabeling and is central to enabling the proposed task.
- **The paper includes an external blind-test evaluation rather than only in-distribution testing.** Although the blind set is small, testing on 38 unseen clinical images and still obtaining average Dice 0.92 / loosening accuracy 0.93 is a meaningful step beyond purely internal validation.
- **The segmentation results themselves look plausibly strong and are reported per zone.** Table 1 gives per-zone Dice scores in the 0.93–0.96 range on the internal split, and Table 4 shows only moderate degradation on the blind set, which suggests the model is at least learning the intended anatomical partitioning rather than only memorizing a trivial mask.
- **The paper includes task-specific interpretability visualizations.** The Grad-CAM figures are not decisive evidence, but they are at least targeted to the relevant implant boundaries / suspected radiolucent regions rather than being generic saliency add-ons.

## Weaknesses

###: Fatal

### Major:
- **The evaluation protocol is internally inconsistent, which materially weakens confidence in the reported numbers.** Section 4 states that the 187 fit images were split 70:30 into 130/57 train/test and then says “to ensure repeatability of results we have performed 5-fold cross-validation and the reported results are the average values of this cross-validation.” But Section 4.1 separately says Stage 1 used an 80:20 split because of limited samples, and Table 2 appears to report a single 57-image test confusion matrix. As written, it is unclear which reported metrics are from a fixed holdout split versus averaged across folds. For a paper whose main claims are empirical, this ambiguity is a serious problem.
- **The evidence for the Stage-1 fit/not-fit screening claim is too weak for the strength of the claim.** The paper states that only **19 of 206** images were labeled not fit, apparently by the same expert who annotated the dataset, and reports only **accuracy (94%)** for this task. With such severe class imbalance, accuracy alone is not enough; the clinically important question is recall/sensitivity for not-fit cases. The paper provides no confusion matrix, no class-wise precision/recall, and no variance estimate for this stage.
- **The paper does not validate the central methodological claim that the multi-stage design itself is responsible for the gains.** The main contribution is framed as a 3-stage pipeline, but there is no ablation comparing: direct image-level classification, zone-wise classification without Stage-2 pretraining, simpler segmentation/classification pipelines, or end-to-end multitask alternatives. The paper shows the full pipeline works on this dataset; it does not show that this decomposition is necessary or superior.
- **The superiority claim over prior methods is not convincingly supported by Table 3.** The proposed method uses richer supervision—expert zone masks and zone-wise labels—whereas the compared prior methods are presented as image-level loose/control classifiers. Since the proposed system benefits from additional structured annotations and a different prediction setup, Table 3 does not establish an apples-to-apples methodological win. This matters because outperforming prior work is one of the paper’s headline empirical claims.
- **The dataset is very small for the breadth of claims about robustness and reliability.** Stages 2–3 are trained on only **130 images** and tested on **57**, while the blind test uses **38** images. On such small sample sizes, a one- or two-case difference can move accuracy by several points. The blind test is valuable, but it is still too small and underdescribed to fully support broad claims of robustness or reliable clinical deployment.

### Minor
- **Annotation reliability is insufficiently documented given how central the labels are.** Section 3.1 says the images were “meticulously annotated by an orthopedic surgeon,” but the paper does not describe annotation protocol, whether more than one expert was involved, or any inter-rater/intra-rater consistency check. Since the paper itself motivates automation partly via reduction of inter-observer variability, this omission is a genuine limitation.
- **Stage 3 is conceptually under-specified in a way that creates technical confusion.** The paper describes Stage 3 as a zone-wise 3-class classification problem (“control / loose / not visible”) with a classification head, but then introduces “Exponential Logarithmic Loss” incorporating dice and cross-entropy. Dice-style terms are natural for segmentation; for a classification head this needs clearer explanation. As written, the reader cannot tell whether Stage 3 is actually zone-level classification, pixel-level radiolucency segmentation within zones, or some hybrid.
- **The handling of the “not visible” class is not evaluated clearly.** The paper motivates a third zone-level class for “not visible,” and even says such cases should trigger expert review/rescan, but the main image-level confusion matrix in Table 2 is purely binary (control/loose). It remains unclear how not-visible zones affect final image-level prediction and whether such cases were included or excluded in the reported classification results.
- **There is no end-to-end error propagation analysis across stages.** Since Stage 3 depends on Stage-2 segmentation outputs and Stage 1 can reject images, the practical behavior of the full pipeline depends on upstream errors. The paper reports per-stage results, but not how often Stage-3 failures are caused by segmentation mistakes or image-fitness mistakes.

### Trivial
- **Table 2’s confusion-matrix terminology is mislabeled / counterintuitive.** The cell for actual control / predicted control is labeled “True Positive,” and actual loose / predicted loose is labeled “True Negative.” This may be only a labeling issue rather than a computation error, but it unnecessarily reduces trust in the evaluation section.
- **Some claims in the abstract/conclusion overreach the actual evaluation.** For example, the paper mentions helping identify “early signs of loosening” and monitoring progression, but no longitudinal or progression-based evaluation is performed.

## Nice-to-Haves
- Add standard segmentation baselines on the same splits for Stage 2 (e.g., strong U-Net-family baselines) to contextualize the reported Dice.
- Report variance or confidence intervals, especially for the 57-image internal test and 38-image blind test.
- Include failure-case analysis for segmentation and loosening classification, especially the single false negative in Table 2 and examples with partially visible zones.
- Report inference time / workflow cost per stage if the clinical-use framing is important.

## Removed Points
These points are flagged to be removed, treat them with caution.

- **Requests to discuss or add missing related work.** Per instruction, I am not including criticisms about omitted prior papers beyond what is directly verifiable from the submission.
- **Formatting/style nitpicks such as grammar, citation style, figure layout, or “Conv1d” vs. “Conv2D” in Figure 4.** These are real polish issues but not substantive review points for the final meta-review.
- **Criticisms about release status / availability / independent verifiability of datasets or references.** If the paper cites the dataset or prior work, that is not grounds for criticism here.
- **Demands for theoretical proofs or extensive mathematical formalization of a primarily empirical medical-imaging pipeline.** That would be outside normal expectations for this kind of submission.
- **Generic strength claims such as “the paper is well-written” or “the topic is important.”** Those are too generic to retain as core strengths.

## Novel Insights
The paper’s strongest aspect is not architectural novelty—the models are fairly standard—but the reframing of implant loosening assessment into a **structured, zone-aware prediction problem** aligned with clinical protocols. That makes the work more interesting as a task-and-annotation contribution than as a methodological deep learning paper. However, that also shifts the burden of proof: once the main novelty is the structured formulation and staged clinical workflow, the submission must be especially rigorous about evaluation protocol, label quality, and demonstrating that the staged design is actually beneficial. Right now, the paper shows promise as a clinically motivated benchmark/pipeline, but not yet as a convincingly validated ICLR-level method paper.

## Suggestions
- **Clarify the evaluation protocol unambiguously.** State exactly which numbers are from holdout splits, which are cross-validation averages, and how Tables 1–4 were computed.
- **Strengthen Stage-1 evaluation.** Report confusion matrix, sensitivity/specificity, precision/recall for the not-fit class, and ideally repeated-split or CV performance.
- **Add ablations that isolate the contribution of each stage.** At minimum: remove Stage 1, remove Stage-2 initialization for Stage 3, compare to direct image-level classification, and compare to direct zone-wise classification without staged training.
- **Make Stage 3 technically precise.** Specify the exact inputs, output granularity, target labels, and why the chosen loss is appropriate for that prediction setup.
- **Document annotation quality better.** Even if only one surgeon annotated the full set, obtaining a second expert on a subset would substantially strengthen the paper.
- **Temper claims of robustness/clinical utility unless supported by stronger evidence.** The current results are promising, but the small dataset sizes and protocol ambiguity make strong claims premature.

## Score and Decision
**Novelty:** Moderate at the task/formulation level, limited at the model level.  
**Technical soundness:** Mixed; the pipeline is plausible, but the evaluation protocol ambiguity and under-validated staged design are significant issues.  
**Empirical support:** Promising but insufficient for the strongest claims; external testing helps, but the dataset sizes are small and comparisons are not fully fair.  
**Significance:** Potentially meaningful clinically, especially if the annotations are released and the evaluation is tightened.  
**Clarity:** Reasonable overall, but key experimental details are confusing in ways that matter.

Relative to the calibration examples, this paper is stronger than generic “apply standard CNNs to a small medical dataset” submissions because it has a more structured clinical formulation, added annotations, and at least some external validation. However, it still falls short of ICLR acceptance because the core empirical claims are not established with enough rigor, and the main methodological thesis (that the multi-stage approach is the source of the gains) is unproven.

**Score: 4.4**  
**Decision: Reject**

MY FINAL SCORE: <pineapple>4.4</pineapple>
MY FINAL DECISION: <orange>Reject</orange>